Here, we demonstrate that Everolimus prevented the activation of NF-κB by inhibiting the phosphorylation and degradation of IκBα, suggesting a promising therapeutic effect of Everolimus in H. pylori-associated gastric diseases. This evidence concerns the gene NFKBIA and stomach disorder.